Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

August 31, 2007

Conditions
Glabellar Frown Lines
Interventions
DRUG

Botulinum neurotoxin type A, free of complexing proteins

Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.

DRUG

Placebo

Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.

Trial Locations (1)

60318

Merz Pharmaceuticals GmbH, Frankfurt

Sponsors
All Listed Sponsors
lead

Merz Pharmaceuticals GmbH

INDUSTRY

NCT00430586 - Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines | Biotech Hunter | Biotech Hunter